Menu Search
Equities

Paragon 28 Inc

FNA:NYQ

Paragon 28 Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)10.04
  • Today's Change-0.39 / -3.74%
  • Shares traded909.82k
  • 1 Year change-1.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Paragon 28 Inc grew revenues 19.30% from 181.38m to 216.39m while net income improved from a loss of 67.33m to a smaller loss of 47.84m.
Gross margin75.22%
Net profit margin-25.75%
Operating margin-20.77%
Return on assets-21.19%
Return on equity-37.86%
Return on investment-25.76%
More ▼

Cash flow in USDView more

In 2023, Paragon 28 Inc increased its cash reserves by 96.63%, or 37.17m. Cash Flow from Financing totalled 128.65m or 59.45% of revenues. In addition the company used 63.89m for operations while cash used for investing totalled 26.99m.
Cash flow per share-0.5365
Price/Cash flow per share--
Book value per share1.67
Tangible book value per share1.11
More ▼

Balance sheet in USDView more

Paragon 28 Inc has a Debt to Total Capital ratio of 44.24%, a higher figure than the previous year's 21.83%.
Current ratio3.50
Quick ratio1.60
Total debt/total equity0.7934
Total debt/total capital0.4424
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 33.55%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		18.42
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.